Literature DB >> 16939945

New challenges and opportunities in managing substance abuse in Malaysia.

Mahmud Mazlan1, Richard S Schottenfeld, Marek C Chawarski.   

Abstract

Until recently, Malaysia has lagged behind in the treatment of drug addiction and related disorders, despite experiencing severe drug problems. By the end of 2004, 234,000 heroin users or heroin-dependent individuals had been registered in the official government registry, but other estimates exceed 500,000 for heroin abusers in the country. Amphetamine-type stimulant abuse is also increasing and of considerable public and government concern. Among the population of drug users, HIV and other infectious diseases rates are very high. In the Western Pacific regions, Malaysia has the second highest HIV prevalence (after Vietnam) among adult populations (0.62%) and the highest proportion of HIV cases resulting from injection drug use (76.3%). Drug use and related disorders exert a heavy burden on the country's health care and legal systems. Historically, drug abusers were rehabilitated involuntarily in correctional, rather than health-care, facilities. This primarily criminal treatment approach had limited effectiveness which led to widespread public dissatisfaction and the recent introduction of medical treatments for addiction. Naltrexone was introduced in 1999; buprenorphine was introduced in 2001 and methadone in 2003. Agonist maintenance programmes were embraced rapidly by the medical community in Malaysia. Currently, over 30,000 opiate-dependent patients are treated with agonist maintenance treatments by more than 500 medical practitioners in Malaysia. Despite these recent advances, treatments for amphetamine-type stimulant abuse or dependence are underdeveloped, and diversion of agonist medications is an emerging concern.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939945     DOI: 10.1080/09595230600883354

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  13 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.

Authors:  Aishwarya Vijay; Alexander R Bazazi; Ilias Yee; Adeeba Kamarulzaman; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2015-02-18

Review 3.  The globalization of addiction research: capacity-building mechanisms and selected examples.

Authors:  Richard A Rawson; George Woody; Thomas F Kresina; Steven Gust
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

4.  Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mehmet Sofuoglu; Weng-Tink Chooi; Norzarina M Zaharim; M Azhar M Yasin; Imran Ahmad; Sharifah Zubaidiah Syed Jaapar; B Kasinather Vicknasingam
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

5.  Profile of clients attending a methadone clinic.

Authors:  Sabrina Anne Jacob; Fauziah Mohammed; Mohamed Azmi Ahmad Hassali
Journal:  Malays J Med Sci       Date:  2015 Jan-Feb

6.  Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia.

Authors:  Muhammad Muhsin Zahari; Woong Hwan Bae; Nor Zuraida Zainal; Hussain Habil; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2010-01       Impact factor: 3.829

Review 7.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

8.  Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia.

Authors:  P Choi; R Kavasery; M M Desai; S Govindasamy; A Kamarulzaman; F L Altice
Journal:  Int J STD AIDS       Date:  2010-06       Impact factor: 1.359

9.  Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide.

Authors:  Jennifer Prah Ruger; Marek Chawarski; Mahmud Mazlan; Craig Luekens; Nora Ng; Richard Schottenfeld
Journal:  Health Serv Res       Date:  2011-10-18       Impact factor: 3.402

10.  Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mahmud Mazlan
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.